Machine Learning Approaches in Diagnosis, Prognosis and Treatment Selection of Cardiac Amyloidosis

Int J Mol Sci. 2023 Mar 16;24(6):5680. doi: 10.3390/ijms24065680.

Abstract

Cardiac amyloidosis is an uncommon restrictive cardiomyopathy featuring an unregulated amyloid protein deposition that impairs organic function. Early cardiac amyloidosis diagnosis is generally delayed by indistinguishable clinical findings of more frequent hypertrophic diseases. Furthermore, amyloidosis is divided into various groups, according to a generally accepted taxonomy, based on the proteins that make up the amyloid deposits; a careful differentiation between the various forms of amyloidosis is necessary to undertake an adequate therapeutic treatment. Thus, cardiac amyloidosis is thought to be underdiagnosed, which delays necessary therapeutic procedures, diminishing quality of life and impairing clinical prognosis. The diagnostic work-up for cardiac amyloidosis begins with the identification of clinical features, electrocardiographic and imaging findings suggestive or compatible with cardiac amyloidosis, and often requires the histological demonstration of amyloid deposition. One approach to overcome the difficulty of an early diagnosis is the use of automated diagnostic algorithms. Machine learning enables the automatic extraction of salient information from "raw data" without the need for pre-processing methods based on the a priori knowledge of the human operator. This review attempts to assess the various diagnostic approaches and artificial intelligence computational techniques in the detection of cardiac amyloidosis.

Keywords: AL amyloidosis; ATTRwt amyloidosis; artificial intelligence; cardiac amyloidosis; deep learning; diagnosis; hypertrophic cardiomyopathy; machine learning; multiple myeloma.

Publication types

  • Review

MeSH terms

  • Amyloid
  • Amyloidosis* / diagnosis
  • Amyloidosis* / pathology
  • Amyloidosis* / therapy
  • Artificial Intelligence
  • Cardiomyopathies* / diagnosis
  • Cardiomyopathies* / pathology
  • Cardiomyopathies* / therapy
  • Humans
  • Machine Learning
  • Quality of Life

Substances

  • Amyloid

Grants and funding

This research received no external funding.